Development of a Potent Protein Degrader against Oncogenic BCR-ABL Protein

DOI Web Site Web Site PubMed 被引用文献3件 参考文献64件
  • Shibata Norihito
    Divisions of Molecular Target and Gene Therapy Products, National Institute of Health Sciences
  • Ohoka Nobumichi
    Divisions of Molecular Target and Gene Therapy Products, National Institute of Health Sciences
  • Hattori Takayuki
    Divisions of Molecular Target and Gene Therapy Products, National Institute of Health Sciences
  • Naito Mikihiko
    Divisions of Molecular Target and Gene Therapy Products, National Institute of Health Sciences

この論文をさがす

抄録

<p>Chromosomal translocation occurs in some cancer cells, resulting in the expression of aberrant oncogenic fusion proteins that include BCR-ABL in chronic myelogenous leukemia (CML). Inhibitors of ABL tyrosine kinase, such as imatinib and dasatinib, exhibit remarkable therapeutic effects, although emergence of drug resistance hampers the therapy during long-term treatment. An alternative approach to treat CML is to downregulate expression of the BCR-ABL protein. Recently, we have devised a protein knockdown system by hybrid molecules named Specific and Nongenetic inhibitor of apoptosis protein [IAP]-dependent Protein Erasers (SNIPER). This system is designed to induce IAP-mediated ubiquitylation and proteasomal degradation of target proteins. In this review, we describe the development of SNIPER against BCR-ABL, and discuss the features and prospect for treatment of CML.</p>

収録刊行物

被引用文献 (3)*注記

もっと見る

参考文献 (64)*注記

もっと見る

関連プロジェクト

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ